Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
Sign in with Google. Opens in new tab
ENTITY
SMARTSCORE: 3.2/5
Medy Tox Inc (086900 KS)
Watchlist
56
Analysis
Health Care
•
South Korea
Medy-Tox Inc. is a biopharmaceutical company. The Company researches, develops and manufactures biopharmaceutical products using clostridium botulinum which is a microorganism toxin.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bearish
•
Hugel Inc
•
14 Aug 2021 21:44
The Fight to Acquire Hugel - GS Group Led Consortium or Goldman Sachs Led Consortium?
The fight to acquire Hugel Inc (145020 KS) is now finally down to between the GS Group led consortium and the Goldman Sachs led consortium.
Douglas Kim
Follow
499 Views
Share
bullish
•
SK Bioscience
•
25 Apr 2021 20:56
KOSPI200 Index Rebalance Preview: Review Period Almost Complete; Short Selling Commences in a Week
There could be up to 6 inclusions and 8 exclusions at the KOSPI200 index review in June. The inclusions could outperform the exclusions as short...
Brian Freitas
Follow
433 Views
Share
bearish
•
LG Chem Ltd
•
14 Apr 2021 20:15
LGChem/SKI Deal - Another Korea Discount Worry? Follow the Female Lead
IP protection is a big worry for Korean firms - has the 2 precedent cases in Korea in 2021 lower the value of IP from the view of international...
Ken S. Kim
Follow
358 Views
Share
bullish
•
Medy Tox Inc
•
28 Jul 2020 00:11
Medytox Rights Offer: Terms & Situations
Medytox, which used to be one of the bluechip names on KOSDAQ, announces a ₩130bil rights offering.It offers a total of 0.97M shares, which...
Sanghyun Park
Follow
561 Views
Share
bearish
•
Hugel Inc
•
29 Jun 2020 10:11
Hugel Placement: A 5.2% Block Deal Sale
After the market close today, it was reported that BK Medical Group’s Chairman Dr. Kim Byung-Gun and Dr. BK Corp will sell their 5.2% stake...
Douglas Kim
Follow
414 Views
Share
First
Previous
2
3
4
5
6
7
8
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.53.10
x